Inside the AstraZeneca Deal That Could Send Summit Therapeutics Stock Up 126%
The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating…
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Me…
Chinese biopharma stocks rally as U.S. signals openness to drug licensing
[Stock market data with uptrend vector] sitox * Shares in Chinese biopharma stocks rose on Monday, with Innovent Biologics (IVBIY [https://seekingalpha.com/symbol/IVBIY]) rising 7% and Akeso (AKESF) up 8% after a report that the U.S. may a…
Akeso (SEHK:9926) Stock Still Looks Cheap Despite Its 141% Run
Akeso has seen sharp swings in sentiment over the past few years, and investors now have fresh clinical data and a discounted cash flow lens to test whether the current share price is actually supported by the cash the business may generat…
Is Akeso (SEHK:9926) Cheap As Its New Trial Clearance Puts Valuation Back In Focus?
Akeso (SEHK:9926) has put fresh attention on its pipeline after securing Phase I clinical trial clearance in China for AK158D1, a bispecific antibody drug conjugate targeting EGFR and TROP2 in advanced solid tumors. Against that backdrop,…
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I c…
Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303)…
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
[Human Respiratory System] nopparit/iStock via Getty Images Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK [https://seekingalpha.com/s…
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months PD-L1 High Expression Subgroup: Hazard Ratio = 0.58 Summit is Conducting Global Phase III…
Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303)…
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab
Summit Therapeutics Inc. (NASDAQ:SMMT) said partner Akeso reported a statistically significant overall survival benefit for ivonescimab monotherapy over pembrolizumab in a prespecified interim analysis of Phase 3 HARMONi-2. The randomized,…
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
Summit Therapeutics (NASDAQ:SMMT) has seen its share price surge by 28.19 percent week-on-week, primarily driven by the positive results of an ongoing clinical trial for its bispecific antibody, ivonescimab. In an updated report during the…
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda. Continue Reading
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up. Continue Reading
Summit Therapeutics in focus as its lung cancer drug shows survival benefit
* Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) said on Wednesday that partner Akeso (AKESF [https://seekingalpha.com/symbol/AKESF]) reported positive overall survival results [https://seekingalpha.com/pr/20639170-ivone…
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
Summit is Conducting HARMONi-7 in Patients with PD-L1 High-Expressing NSCLC MIAMI, September 02, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS…
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
HONG KONG, Sept. 2, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat…
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global imm…
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Shares of Summit Therapeutics SMMT rose 6.5% on Wednesday after the company's partner Akeso announced positive top-line results from the phase III HARMONi-GI1 study conducted in China in certain patients with biliary tract cancer (BTC). Th…
Summit Therapeutics (SMMT) Is Up 8.5% After New Phase III Biliary Cancer Data For Ivonescimab
Summit Therapeutics reported that partner Akeso recently delivered positive topline Phase III HARMONi-GI1 data from China, where ivonescimab plus chemotherapy achieved statistically significant and clinically meaningful overall survival, p…
Sector Update: Healthcare Stocks Fall Wednesday Afternoon
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy First Phase III Ivonescimab Readout beyond NSCLC Demonstrates Significant OS Benefit MI…
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that a pre-specified interim analysis assessed by the Independent Data Monitoring Committee (IDMC) of the randomized, controll…
Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearanc…
Akeso (SEHK:9926) Wins China Lung Cancer Approval As Breast Cancer Trial Begins
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Akeso (SEHK:9926) secured regulatory approval in China for ivonescimab plus chemotherapy as a first…
Summit higher as partner Akeso wins China label expansion for lead drug
[Approved red stamp sign.] * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) traded higher on Wednesday after the Chinese drug regulator, the National Medical Products Administration, approved a label expansion…
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Stati…
Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment
HONG KONG, Aug. 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the China National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for ivonesci…
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TRO…
Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer
HONG KONG, July 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase Ib/II clinical study (AK138D1-201) evaluating its internally developed next-generati…
Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
HONG KONG, July 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 b…
Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study eva…
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Summit Therapeutics Inc. (NASDAQ:SMMT) withdrew a $500 million proposed underwritten public offering it ha…
Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were…